Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts Running title: Evolution of HT use in France

Agnès Fournier 1 Céline Kernaleguen 1 Henri Panjo 2, 3 Françoise Clavel-Chapelon 1, * Virgine Ringa 3, 2
* Auteur correspondant
1 Equipe 9 - Générations et santé (Mode de vie, gènes et santé : épidémiologie intégrée trans-générationnelle)
UVSQ - Université de Versailles Saint-Quentin-en-Yvelines, UP11 - Université Paris-Sud - Paris 11, CESP - Centre de recherche en épidémiologie et santé des populations, IGR - Institut Gustave Roussy, INSERM - Institut National de la Santé et de la Recherche Médicale : U1018
2 Equipe 7 - Sexualité et soins (Genre, Sexualité, Santé)
UVSQ - Université de Versailles Saint-Quentin-en-Yvelines, UP11 - Université Paris-Sud - Paris 11, CESP - Centre de recherche en épidémiologie et santé des populations, INSERM - Institut National de la Santé et de la Recherche Médicale : U1018
3 INED - Institut national d'études démographiques
Abstract : The current evaluation of the benefit/risk ratio associated with menopausal hormone therapy (MHT) use is largely based on clinical trials which investigated the effects of oral treatments. Would MHT with transdermal estrogens be associated with a more favourable benefit/risk ratio? We reviewed the available epidemiologic evidence on that question. Epidemiologic studies were considered if they provided risk estimates of conditions which carry an important weight among menopausal women, and for which epidemiologic evidence of a possible link with MHT use is convincing: cardiovascular diseases, breast cancer, diabetes, colorectal cancer and hip fracture. We did not include studies with only surrogate measures. We found that the available information on the potential impact of the route of administration of MHT on the risk of our selected outcomes is limited. To date, epidemiologic data suggest that it has no impact on the risk of breast cancer and hip fracture. Results on the risk of coronary heart disease and colorectal cancer are inconsistent. Studies on stroke and diabetes risk are too few to allow meaningful conclusions. There is a suggestion that transdermal MHT may be less deleterious than oral MHT regarding venous thromboembolism which needs to be confirmed. The issue of the route of administration of MHT should remain an active area of research as part of an attempt to identify treatment modalities that would have the least potential for exerting adverse effects.
Keywords : Epidemiology menopausal hormone therapy oral estrogens transdermal
Type de document :
Article dans une revue
Menopause, Lippincott, Williams & Wilkins, 2011, 18 (2), pp.219-23. 〈10.1097/gme.0b013e3181ecf3ec〉
Liste complète des métadonnées

Littérature citée [15 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-01320290
Contributeur : Agnès Fournier <>
Soumis le : lundi 23 mai 2016 - 16:08:06
Dernière modification le : mercredi 12 septembre 2018 - 01:28:38

Fichiers

Short_report_révisé_untracke...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

INED | UVSQ | CESP | IGR | FNCLCC | UNIV-HESAM

Citation

Agnès Fournier, Céline Kernaleguen, Henri Panjo, Françoise Clavel-Chapelon, Virgine Ringa. Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts Running title: Evolution of HT use in France. Menopause, Lippincott, Williams & Wilkins, 2011, 18 (2), pp.219-23. 〈10.1097/gme.0b013e3181ecf3ec〉. 〈inserm-01320290〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

146

Téléchargements de fichiers

114

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD